(firstQuint)Phase II Study of ASP3550 in Patients With Prostate Cancer.

 Two doses of ASP3550 were administered to patients with prostate cancer.

 The primary efficacy variable was the effect of ASP3550 on the maintenance of serum testosterone suppression.

 In addition, the safety and pharmacokinetics of ASP3550 will be investigated.

.

 Phase II Study of ASP3550 in Patients With Prostate Cancer@highlight

To assess the effect of ASP3550 on the maintenance of serum testosterone suppression in patients with prostate cancer